Coupling head and neck screening with lung cancer screening could improve survival

Adding head and neck cancer screenings to recommended lung cancer screenings would likely improve early detection and survival, according to a multidisciplinary team whose results were published in Cancer (2015; doi:10.1002/cncr.29189).

The team provided a rationale for a national clinical trial to assess the effectiveness of adding examination of the head and neck to lung cancer screening programs. People most at risk for lung cancer are also those most at risk for head and neck cancer.

Scientists affiliated with the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC Cancer Center in Pennsylvania, led the study, which was funded by the National Institutes of Health (NIH).

"When caught early, the 5-year survival rate for head and neck cancer is over 83%," said senior author Brenda Diergaarde, PhD, of UPCI. "However, the majority of cases are diagnosed later when survival rates generally shrink below 50%. There is a strong need to develop strategies that will result in identification of the cancer when it can still be successfully treated."

Head and neck cancer is the world's sixth-most common type of cancer. Worldwide every year, it is diagnosed in 600,000 people and approximately 350,000 die from their disease. Tobacco use and alcohol consumption are the major risk factors for developing the cancer.

The early symptoms are typically a lump or sore in the mouth or throat, trouble swallowing, or a voice change, which are often brushed off as a cold or something that will heal. Treatment, particularly in later stages, can be disfiguring and can change the way a person talks or eats.

Diergaarde and her team analyzed the records of 3,587 people enrolled in the Pittsburgh Lung Screening Study (PLuSS), which consists of current and ex-smokers ages 50 years and older, to see if they had a higher chance of developing head and neck cancer.

In the general US population, fewer than 43 cases per 100,000 people would be expected to develop head and neck cancer annually among those 50 years and older. Among the PLuSS participants, the rate was 71.4 cases annually per 100,000 people.

Recently, the US Preventive Services Task Force, as well as the American Cancer Society and several other organizations, recommended annual screening for lung cancer with low-dose computed tomography in people ages 55 to 74 years with a smoking history averaging at least a pack a day for a total of 30 years. The recommendation came after a national clinical trial showed that such screening reduces lung cancer mortality.

"Head and neck cancer is relatively rare, and screening the general population would be impractical," said co-author David O. Wilson, MD, MPH, associate director of UPMC's Lung Cancer Center. "However, the patients at risk for lung cancer whom we would refer for the newly recommended annual screening are the same patients that our study shows also likely would benefit from regular head and neck cancer screenings. If such screening reduces mortality in these at-risk patients, that would be a convenient way to increase early detection and save lives."

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs